Clinical trials: Chronic Infection
Hepatitis C, Chronic
Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)
This study will evaluate the safety, tolerability, and antiviral activity of grazoprevir (MK-5172) when administered concomitantly with peg-interferon alfa-2b (Peg-IFN) and ribavirin (RBV) to treatment-naïve participants with…
- Trial name
- NCT01440595
- Testing
- Grazoprevir, Peginterferon alfa-2b (Peg-IFN), Ribavirin (RBV)
- Volunteers
- 5 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1
This trial will test the hypothesis that CF102 can safely and effectively suppress viral load in patients with chronic hepatitis C and high circulating levels of virus.
- Trial name
- NCT00790673
- Testing
- CF 102
- Where
- Israel
- Volunteers
- 32 people
- Sponsor
- Can-Fite BioPharma
Hepatitis C, Chronic
Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients
The aim of this study is to determine if treatment monitoring schedule for chronic HCV patients treated with glecaprevir (300mg)/pibrentasvir (120mg) can be simplified.
- Trial name
- SMART-C (NCT03117569)
- Testing
- glecaprevir (300mg)/pibrentasvir (120mg)
- Where
- 33 sites in United States, Australia and 6 more
- Volunteers
- 380 people
- Sponsor
- Kirby Institute
Hepatitis C, Chronic
Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.
This single arm study will evaluate the efficacy and safety of PEGASYS (180 micrograms sc weekly) plus ribavirin (1000-1200mg po daily) in treatment-naive Latino patients versus non-Latino Caucasian patients with chronic…
- Trial name
- NCT00107653
- Testing
- Ribavirin, Peginterferon alfa-2a
- Where
- 60 sites in United States, Puerto Rico
- Volunteers
- 569 people
- Sponsor
- Hoffmann-La Roche
Leukemia, Lymphoma
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
RATIONALE: Giving chemotherapy with or without total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00547196
- Testing
- filgrastim, Busulfan, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Hepatitis C, Chronic
The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study
Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) offers a cure to those with chronic HCV infection. For marginalized communities, linkage to care services often aren't enough to overcome barriers to accessing the…
- Trial name
- NOW (NCT03987503)
- Testing
- Epclusa (SOF/VEL), Standard of care, Fibroscan® 430 Mini Plus
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Chronic Hepatitis B
Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection
The primary objective of this study is to evaluate the antiviral efficacy of tenofovir disoproxil fumarate (tenofovir DF; TDF) versus placebo in pediatric population (aged 2 to < 12 years at the time of enrollment) with chronic…
- Trial name
- NCT01651403
- Testing
- Tenofovir DF
- Where
- 21 sites in United States, India and 3 more
- Volunteers
- 90 people
- Sponsor
- Gilead Sciences
HBeAg-negative Chronic Hepatitis B
Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen
The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis…
- Trial name
- NCT01940341
- Testing
- TAF, TDF
- Where
- 105 sites in United States, Australia and 15 more
- Volunteers
- 426 people
- Sponsor
- Gilead Sciences
Cancer
Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)
RATIONALE: Mycophenolate mofetil added to immunosuppressive treatment regimens may be effective in treating newly diagnosed chronic graft-versus-host disease caused by stem cell transplantation.
- Trial name
- NCT00089141
- Testing
- mycophenolate mofetil
- Where
- 16 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Martin, Paul
Tracheitis, Tracheobronchitis
Evaluation of Effectiveness of the Treatment After Repeated Administration of Klacid®SR
This post-marketing observational study (PMOS) will be conducted in a prospective, single-arm, single-country, multicenter format.
- Conditions
- Tracheitis, Tracheobronchitis, Bronchitis, Chronic Bronchitis
- Trial name
- NCT01130883
- Where
- 135 sites in Czechia
- Volunteers
- 3,130 people
- Sponsor
- Abbott
Hepatitis C
Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment
The study is to investigate whether participants with hepatitis C virus (HCV) genotype 1 who have a history of non-response/relapse to peginterferon alfa-2a (PEG) and ribavirin (RBV) may benefit from treatment with triple therapy…
- Trial name
- NCT01183169
- Testing
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Where
- 75 sites in United States, Australia and 12 more
- Volunteers
- 459 people
- Sponsor
- Debiopharm International SA
Hepatitis C, Chronic, Hepatitis C
Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)
Enrolled patients will be recruited to two parallel groups during therapy for Hepatitis C. Patients in the first one will receive a patient assistance program, and patients in the second group will not.
- Trial name
- NCT00728494
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908), Patient Assistance Program
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Anemia, Cancer Fatigue
Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia
This phase II trial studies the side effects of ex vivo-activated autologous lymph node lymphocytes infusion and to see how well they work in treating patients with chronic lymphocytic leukemia.
- Conditions
- Anemia, Cancer Fatigue, Chronic Lymphocytic Leukemia, Fever
- Trial name
- NCT02530515
- Testing
- Ex Vivo-activated Autologous Lymph Node Lymphocytes, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatitis C, Chronic
A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
This multi-center, open-label study will evaluate the efficacy and safety of Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) in relation to IL28-b gene expression in treatment-naïve patients with chronic hepatitis C…
- Trial name
- NCT01447420
- Testing
- peginterferon alfa-2a, ribavirin [Copegus]
- Where
- 15 sites in Brazil
- Volunteers
- 129 people
- Sponsor
- Hoffmann-La Roche
Chronic Obstructive Pulmonary Disease
Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is a progressive disorder of the lung parenchyma and airways, which is the third-leading cause of death in the USA.
- Trial name
- Quercetin (NCT01708278)
- Testing
- Quercetin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Michigan
Hepatitis C
Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)
The objective of this trial is to evaluate the efficacy and safety of two different treatment regimens with BI 201335, both in combination with PegIFN/RBV) as compared to standard of care (SOC) with PegIFN/RBV alone.
- Trial name
- NCT01343888
- Testing
- PegIFN/RBV, BI 201335
- Where
- 98 sites in Austria, Belgium and 9 more
- Volunteers
- 656 people
- Sponsor
- Boehringer Ingelheim
Chronic Hepatitis C
Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)
Open label phase 2a study of two week treatment with CDI-31244 and sofosbuvir and veltapasvir followed by four week treatment of sofosbuvir and velpatasvir in individuals with chronic hepatitis C (HCV) genotype 1 (GT1) infection
- Trial name
- NCT03501550
- Testing
- CDI-31244, SOF/VEL
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Cocrystal Pharma, Inc.
Hepatitis C
Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients
The purpose of this study is to follow-up with participants from feeder studies who achieved sustained virologic response (SVR) over 24 hours posttreatment (SVR24), to assess durability of SVR, and to assess the changes in liver…
- Trial name
- NCT02753699
- Testing
- Alisporivir
- Where
- 119 sites in United States, Argentina and 20 more
- Volunteers
- 723 people
- Sponsor
- Debiopharm International SA
Hunter Syndrome
An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients
The objective of this study is to evaluate the effect of anti-idursulfase antibodies on idursulfase safety (measured by infusion related adverse events) between patients who develop anti-idursulfase antibodies and patients who do…
- Trial name
- NCT00882921
- Testing
- Idursulfase
- Where
- 6 sites in United States, Brazil and 1 more
- Volunteers
- 26 people
- Sponsor
- Shire
Hepatitis C, Chronic
4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients
The main purpose of this clinical trial with BI 207127 is to see the effect of 4 week combination of BI 207127 with Peginterferon alfa (Peg-IFN) and Ribavirin (RBV) on hepatitis C virus (HCV) virus load and how safe BI 207127 is…
- Trial name
- NCT00905632
- Testing
- BI 207127 middle dose +SOC, BI 207127 high dose+SOC, BI 207127 low dose + SOC
- Where
- 18 sites in France, Germany and 1 more
- Volunteers
- 75 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.